Jiangsu Nhwa Pharmaceutical Company Limited operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Jiangsu Nhwa Pharmaceutical Company Limited with three other
companies in this sector in China:
China Resources Medical Holdings Co Ltd
sales of 1.88 billion Chinese Renmimbi [US$277.19 million]
of which 46%
was GPO business),
Zhejiang Zhenyuan Co., Ltd.
(2.58 billion Chinese Renmimbi [US$380.55 million]
of which 82%
was Medicine Wholesales), and
China Pioneer Pharma Holdings Ltd
(2.15 billion Chinese Renmimbi [US$317.96 million]
of which 56%
was Products sold via the provision of co-pr).
During the year ended December of 2017, sales at
Jiangsu Nhwa Pharmaceutical Company Limited were 3.39 billion Chinese Renmimbi (US$500.97 million).
increase of 12.5%
versus 2016, when the company's sales were 3.02 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Jiangsu Nhwa Pharmaceutical Company Limited
(and since 2012, sales have increased a total of 71%).
Sales of Other Operation saw an increase
that was more than double the company's growth rate: sales were up
3,348.2% in 2017, from
1.00 million Chinese Renmimbi to 34.62 million Chinese Renmimbi.